Sara Reed is a mental health futurist and has spent her early career reimagining effective mental health care in the medical system. Sara's clinical interests focus on ethical care in psychedelic sessions, examining ways culture informs how we diagnose and treat mental illnesses. Before joining the Centre for Psychedelic Research at Imperial College in London, Sara participated as a study therapist with the MDMA therapy for PTSD clinical trials sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). While working with MAPS, she advocated for health equity in psychedelic therapy and co-led the first ever MAPS MDMA-assisted psychotherapy training for clinicians of color. After this study ended, she received training in psilocybin therapy at Yale University for the "Psilocybin-Induced Neuroplasticity in the Treatment of Major Depressive Disorder" trial and co-wrote a paper using Acceptance and Commitment Therapy as a therapeutic modality in this treatment.

In addition to her appointment at Imperial, Sara co-facilitates psilocybin truffle retreats in the Netherlands. She works in private practice with patients with mood and anxiety disorders using ketamine as an adjunct to psychotherapy. Sara lectures on topics fusing culturally sensitive practices with psychedelic-assisted therapy and advises organizations on anti-oppressive and inclusive practices.